Search research articles
Contact Us
Filters
Showing results (31-40 of 43) with videos related to
Page
of 5
Sort By:
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
|
August 18, 2025
Upadacitinib dose adjustment in moderate-to-severe atopic dermatitis: insights from a multicenter real-world study
Flavia Manzo Margiotta, Valentina Dini, Laura Calabrese, et al.
Giornale Italiano Di Dermatologia E Venereologia : Organo Ufficiale, Societa Italiana Di Dermatologia E Sifilografia
|
September 26, 2018
A multicenter retrospective case-control study on Suspension of TNF-inhibitors and Outcomes in Psoriatic patients (STOP study)
Giuseppe Stinco, Nicola Balato, Cinzia Buligan, et al.
Future Oncology (London, England)
|
December 20, 2014
A rare case of anal porocarcinoma treated by electrochemotherapy
Lorenzo Borgognoni, Borgognoni Lorenzo, Leonardo Pescitelli, et al.
Italian Journal of Dermatology and Venereology
|
November 24, 2023
Efficacy of risankizumab after intra-class switching between anti IL-23 antagonists: a multi-center, retrospective, real-life observation
Flavia Manzo Margiotta, Alessandra Michelucci, Eugenio Capalbo, et al.
Dermatology Practical & Conceptual
|
October 25, 2024
A prospective Real-Life Multicenter Study of Tildrakizumab 200 mg in Patients with Moderate-Severe Psoriasis: Who is the Ideal Patient?
Eugenia Veronica Di Brizzi, Stefano Caccavale, Roberta Di Caprio, et al.
Italian Journal of Dermatology and Venereology
|
July 5, 2022
Tuscany consensus for the treatment of moderate-severe psoriasis: update and focus on practical guidelines for place in therapy of anti-IL-17 and anti-IL-23 biologics
Francesca Prignano, Leonardo Pescitelli, Emanuele Trovato, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
April 16, 2023
Real-life effectiveness of Risankizumab according to body mass index: Results of an Italian multicentre retrospective study
Martina Dragotto, Eugenio Capalbo, Alessandra Cartocci, et al.
Italian Journal of Dermatology and Venereology
|
November 7, 2024
Risankizumab in very elderly patients in real-world practice
Elisa Lorenzoni, Antonella Di Cesare, Elia Rosi, et al.
Dermatology Practical & Conceptual
|
November 14, 2025
Therapeutic Modulation Of Peripheral Blood Cells And Inflammatory Indices During 52 Weeks Of Risankizumab In Responder Patients With Moderate-to-Severe Psoriasis: Results From A Multicenter Prospective Study
Antonella Di Cesare, Elia Rosi, Emanuele Trovato, et al.
Clinical, Cosmetic and Investigational Dermatology
|
April 10, 2023
Efficacy and Safety of Secukinumab in Elderly Patients with Moderate to Severe Plaque-Type Psoriasis: Post-Hoc Analysis of the SUPREME Study
Marina Talamonti, Filomena Russo, Giovanna Malara, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 43) with videos related to
Sort By:
Page
of 5
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
|
August 18, 2025
Upadacitinib dose adjustment in moderate-to-severe atopic dermatitis: insights from a multicenter real-world study
Flavia Manzo Margiotta, Valentina Dini, Laura Calabrese, et al.
Giornale Italiano Di Dermatologia E Venereologia : Organo Ufficiale, Societa Italiana Di Dermatologia E Sifilografia
|
September 26, 2018
A multicenter retrospective case-control study on Suspension of TNF-inhibitors and Outcomes in Psoriatic patients (STOP study)
Giuseppe Stinco, Nicola Balato, Cinzia Buligan, et al.
Future Oncology (London, England)
|
December 20, 2014
A rare case of anal porocarcinoma treated by electrochemotherapy
Lorenzo Borgognoni, Borgognoni Lorenzo, Leonardo Pescitelli, et al.
Italian Journal of Dermatology and Venereology
|
November 24, 2023
Efficacy of risankizumab after intra-class switching between anti IL-23 antagonists: a multi-center, retrospective, real-life observation
Flavia Manzo Margiotta, Alessandra Michelucci, Eugenio Capalbo, et al.
Dermatology Practical & Conceptual
|
October 25, 2024
A prospective Real-Life Multicenter Study of Tildrakizumab 200 mg in Patients with Moderate-Severe Psoriasis: Who is the Ideal Patient?
Eugenia Veronica Di Brizzi, Stefano Caccavale, Roberta Di Caprio, et al.
Italian Journal of Dermatology and Venereology
|
July 5, 2022
Tuscany consensus for the treatment of moderate-severe psoriasis: update and focus on practical guidelines for place in therapy of anti-IL-17 and anti-IL-23 biologics
Francesca Prignano, Leonardo Pescitelli, Emanuele Trovato, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
April 16, 2023
Real-life effectiveness of Risankizumab according to body mass index: Results of an Italian multicentre retrospective study
Martina Dragotto, Eugenio Capalbo, Alessandra Cartocci, et al.
Italian Journal of Dermatology and Venereology
|
November 7, 2024
Risankizumab in very elderly patients in real-world practice
Elisa Lorenzoni, Antonella Di Cesare, Elia Rosi, et al.
Dermatology Practical & Conceptual
|
November 14, 2025
Therapeutic Modulation Of Peripheral Blood Cells And Inflammatory Indices During 52 Weeks Of Risankizumab In Responder Patients With Moderate-to-Severe Psoriasis: Results From A Multicenter Prospective Study
Antonella Di Cesare, Elia Rosi, Emanuele Trovato, et al.
Clinical, Cosmetic and Investigational Dermatology
|
April 10, 2023
Efficacy and Safety of Secukinumab in Elderly Patients with Moderate to Severe Plaque-Type Psoriasis: Post-Hoc Analysis of the SUPREME Study
Marina Talamonti, Filomena Russo, Giovanna Malara, et al.
Page
of 5